Quantum-Si incorporated (QSI) Stock: Price, Forecast & Analyst Target
Quantum-Si incorporated (QSI) — MoonshotScore 28/100 (Weak band), calculated Nov 18, 2026. Price $0.909 (-15.05%), as of the Nov 20, 2026 trading session; market cap $200M.
Listing-status flag — 8-K Item 3.01, filed Jul 24, 2026. Cure deadline stated in filing: Jan 19, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Quantum-Si incorporated · QSI · NASDAQ · Healthcare · Medical - Devices
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Quantum-Si sells a semiconductor-derived platform for detecting individual protein molecules, placing the company closer to an emerging protein-sequencing instrument developer than a conventional medical-device manufacturer. Product adoption remains far too small to absorb the research and commercial cost base. Proteus execution now carries the story: its delayed launch must translate into meaningful demand before persistent cash burn narrows the financing cushion.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Quantum-Si (QSI)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $212,000 (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 5 of the last 8 reports
- Altman Z 2.75 · Piotroski F 1
Holding back: weak fundamentals, a rich price
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.909 | |
| Change on the day | -15.05% | |
| 52-week range | $0.69–$1.81 | |
| Market capitalisation | $200M | — |
| Shares traded on the day | 7.80M | |
| Beta (volatility vs the S&P 500) | 3.25 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Listing notice
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for Quantum-Si (QSI): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 14, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Quantum-Si (QSI), and what does it report?
Short answer · as of
Quantum-Si is developing instruments that apply semiconductor technology to protein sequencing through individual-molecule detection.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Reported revenue is predominantly product sales, with services contributing only a small portion, so the income statement mainly reflects early instrument commercialization rather than a scaled service business. Revenue remains tiny beside research spending and operating losses, making reported growth sensitive to modest changes in product shipments.
What do the latest results show for Quantum-Si (QSI)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $212,000.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
The latest period brought a sequential revenue rebound and stronger gross profit, while operating loss widened as research spending increased. Revenue also surpassed the corresponding analyst estimate after a run of misses, but it remained below levels recorded during much of the preceding series. Operating cash outflow improved from the prior period, though the business still consumed far more cash than it generated in sales.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $212,000 | -$22M | -$0.10 (diluted) |
| Q2 FY2026 | $344,000 | -$24M | -$0.11 (diluted) |
| Q1 FY2026 | $258,000 | -$22M | -$0.10 (diluted) |
| Q4 FY2025 | $451,000 | -$18M | -$0.08 (diluted) |
What are the financial strengths and risks for Quantum-Si (QSI)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Cash and investments substantially exceed debt and liabilities, giving Quantum-Si meaningful room to continue development despite its losses. That protection is eroding: cash and short-term investments have declined materially across the reported window, operating cash flow remains negative, and weak quality screens reflect a business without established earnings support. Management says workforce reductions and expense controls extend funding through the revised Proteus plan, but the delayed launch and a separate Nasdaq listing-status notice make execution and capital preservation inseparable risks.
Data-derived red flags
- Listing risk — at $0.909 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Negative return on equity (-43.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Quantum-Si (QSI)?
Short answer · as of
The Nasdaq listing-cure deadline stated in the company's filing is Jan 19, 2027.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Proteus timing is the most consequential operating marker because management moved the planned launch later while tying its funding horizon to the revised schedule. Before launch, watch whether product revenue sustains its recent rebound, gross profit continues to improve, and operating cash outflow falls without another sharp increase in losses. The scheduled earnings release, subsequent periodic filings, and Nasdaq compliance disclosures should clarify whether commercial traction and liquidity remain aligned with management’s plan.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Quantum-Si compare with its peers?
Short answer
Quantum-Si's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Quantum-Si differs from mature medical-device businesses because its core proposition is semiconductor-enabled protein sequencing, not a broad portfolio of established clinical products. Product sales dominate its limited revenue, while research expense and cash consumption still define the financial profile. Cash and investments represent a large share of market value, so comparison with scaled instrument vendors depends less on current sales multiples and more on whether Proteus can move the company from platform development toward repeatable commercialization.
| Company | Price | Market value | Score |
|---|---|---|---|
| $25.60 Nov 20, 2026 | $573M | 90 5-pillar Nov 18, 2026 | |
| $8.52 Nov 20, 2026 | $323M | 88 5-pillar Nov 18, 2026 | |
| $22.98 Nov 20, 2026 | $188M | 87 5-pillar Nov 18, 2026 | |
| $8.73 Nov 19, 2026 | $351M | 87 5-pillar Nov 18, 2026 | |
| $200.66 Nov 19, 2026 | $30.3B | 84 5-pillar Nov 18, 2026 | |
| $13.23 Nov 20, 2026 | $177M | 71 5-pillar Nov 18, 2026 | |
| $1.49 Nov 20, 2026 | $93.7M | 43 5-pillar Nov 18, 2026 | |
| $3.23 Nov 19, 2026 | $96.5M | 41 5-pillar Nov 18, 2026 | |
| $5.30 Nov 20, 2026 | $138M | 37 5-pillar Nov 18, 2026 | |
| $6.07 Nov 20, 2026 | $247M | 36 5-pillar Nov 18, 2026 | |
| $8.67 Nov 20, 2026 | $361M | 35 5-pillar Nov 18, 2026 | |
| $10.18 Nov 20, 2026 | $566M | 34 5-pillar Nov 18, 2026 | |
| Quantum-Si (QSI) — this page | $0.909 | $200M | 28 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.90 – $4.00
- Consensus target
- $2.95
- Median target
- $2.95
Consensus record · Captured .
Measured against a quoted price of $0.909 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 22, 2026
- Transactions
- 14
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 14
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held QSI in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 0.05% | $7.91M | Added +3.1% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Quantum-Si (QSI)?
- Quantum-Si Demonstrates Detection of All 20 Naturally Occurring Amino Acids
- Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
- Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- H.C. Wainwright Maintains Buy Rating on Quantum-Si
Quantum-Si Healthcare Stock: Key Questions Answered
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered); one answer was revised 2026-10-08 using a reviewed historical filing; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does the Proteus delay matter for Quantum-Si?
Proteus is the company’s major planned launch, and its revised timing pushes the commercial proof point further out while losses and cash consumption continue. Management says cost reductions support the updated plan, making spending discipline as important as launch execution.
Are Quantum-Si sales mainly products or services?
Product revenue dominates, while services contribute only a small share. The reported sales base therefore depends primarily on early product commercialization rather than a substantial service stream.
Can Quantum-Si fund the revised Proteus plan?
Management says current capital, workforce reductions, and other expense actions can fund operations through the revised plan. Cash and investments remain substantial relative to debt, but continuing operating outflows mean that claim depends on disciplined spending and launch progress.
What does the Nasdaq listing-status notice mean for QSI?
Quantum-Si disclosed that Nasdaq had found its shares out of compliance with the minimum bid-price requirement. The filing provided an initial cure period and a conditional path to additional time; it did not immediately delist the shares. The reviewed terms are historical and do not establish current compliance, so later company disclosures remain necessary.
What is the QSI stock price today?
The last price recorded for Quantum-Si incorporated (QSI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the QSI price target?
The analyst consensus price target for Quantum-Si incorporated (QSI), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. A targeted answer was revised on 2026-10-08 using the source dated on that answer. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 30 figures on this page — 6 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com